Protea Appoints David Halverson As President

Formerly The Company’s Vice President & Chief Business Officer


MORGANTOWN, W.Va., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc., (OTCQB:PRGB) announced today that the Company has appointed David Halverson as its President.

“We are pleased to announce the selection of David Halverson as President of Protea Biosciences,” stated Steve Turner, Protea’s Chairman & CEO. He added, “David has led the successful development of our proprietary molecular information services business. He is building a strong and growing customer base, which now includes major pharmaceutical and biotechnology companies; he is ideally suited to manage our business operations, as we position Protea to meet and lead the global demand for better molecular information, for improved pharmaceutical development.”   

David Halverson commented, “I am honored to be appointed to the position of President, as we continue to grow the company and add amazing new capabilities to our expanding portfolio of proprietary Metabolic, Proteomic, Biopharmaceutical, and Mass Spec Imaging workflows.  I have the highest confidence in our Company achieving the leadership position in the new molecular information services industry.”

Prior to his appointment as President, Halverson served as Protea’s Vice President and Chief Business Officer. Before joining Protea, Halverson was employed by Huntingdon Life Sciences in various capacities, including Head of European and US Sales. He has over 20 years of management experience in the pharmaceutical services industry, including serving as a Director of Sales for PPD Discovery and the Quintiles Preclinical Groups. 

About Protea Biosciences

Protea Biosciences Group, Inc. (OTCQB:PRGB) is a leading molecular information company providing proprietary bio-analytical technology to the pharmaceutical and life science industries. "Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company's proprietary technology to identify and characterize the proteins, metabolites, lipids and other biomolecules which are the byproducts of all living cells and life forms.

Protea is a registered trademark of Protea Biosciences Group, Inc.

 


            

Contact Data